“Vista’s View – A Weekly FREE Market Update 10-7-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 10-7-18!”  Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Smallcap Stocks To Watch” section, featured stories & exciting videos from Vista’s Coverage Universe.  

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE updates by signing up today!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




“Vista’s View – A Weekly FREE Market Update 9-29-18″…Now Available!

Vista Partners has published “Vista’s View – A Weekly Market Update Newsletter 9-29-18!”  Each weekly newsletter is written by Vista Partners’ Managing Director, John Heerdink.   Vista’s View includes an exclusive view on the stock market for the week, a “Smallcap Stocks To Watch” section, featured stories & exciting videos from Vista’s Coverage Universe.  

Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more on the website daily.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.  It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE updates by signing up today!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




“Superfirms’ Domination Influences Economic Factors”

Vista Partners (“Vista”) has published September’s FREE Macroeconomic & Investment Monthly Newsletter, “Superfirms’ Domination Influences Economic Factors.”

Vista’s monthly newsletter contains investment considerations for Banks, Biotech, Cloud Services, Energy, Fintech, Healthcare, Manufacturing, Mining, Materials, Nuclear Energy, Real Estate, and Technology.

Vista Partners centers its Coverage on the Dow 30 Components, Select Emerging Growth Companies & Vista’s Featured Companies, with exclusive, broad-based commentary from Managing Director, John F. Heerdink, Jr.

In September’s edition of the Macroeconomic & Investment Newsletter, Mr. Heerdink states,

“An imminent freeze on stock buybacks could challenge the market. With the third quarter coming to a close, as of October 5…….” Read full newsletter.

Companies Featured in September’s Newsletter: 3M (MMM) | Amazon (AMZN) | Apple (AAPL) | Atossa Genetics, Inc. (NASDAQ: ATOS) | | First Majestic Silver Corp. (NYSE: AG) | Fusion, Inc. (NASDAQ: FSNN) | Microsoft (MSFT) | UnitedHealth Group (UNH).

Vista Partners publishes 100% of its content free. Vista Partners offers a wealth of mixed-media resources on the Dow 30 & Select Emerging Growth Companies. To receive FREE email updates from Vista, please sign up at VistaPGlobal.com/signup.

About Vista Partners LLC:

Founded in 2005, Vista Partners LLC (“Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, and Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies, Vista’s Featured Companies, International Companies, Pre-IPO Companies & Strategic Companies.

Contact:

inquiries@VistaPGlobal.com




It’s Time to Read The “Vista Partners Weekly Market Update 9-22-18″…Stay Informed! Stay Competitive!

Vista Partners has published “Vista Partners Weekly Market Update 9-22-18!”  Each weekly issue is written by Vista Partners’ Managing Director, John Heerdink & includes updates on the stock market, a “Smallcap Stocks To Watch” section, & featured stories & videos from Vista’s Coverage Universe.  Vista Covers all Dow 30 components, International Companies, Select Emerging Growth Companies & more.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page Now.

It’s FREE!!!

Stay Informed! Stay Competitive!  Receive our FREE updates by signing up today!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




San Diego-based Fate Therapeutics Enters Strategic Collaboration with Tokyo’s ONO Pharmaceutical Co.

San Diego-based Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company is pioneering the development of off-the-shelf cell therapies using its proprietary induced pluripotent stem cell (iPSC) product platform. The Company’s immuno-oncology pipeline is comprised of FATE-NK100, a donor-derived natural killer (NK) cell cancer immunotherapy that is currently being evaluated in three Phase 1 clinical trials, as well as iPSC-derived NK cell and T-cell immunotherapies, with a focus on developing augmented cell products intended to synergize with checkpoint inhibitor and monoclonal antibody therapies and to target tumor-specific antigens. The Company’s immuno-regulatory pipeline includes ProTmune™, a next-generation donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders.  For more information, please visit www.fatetherapeutics.com.

 

 

 

Fate’s proprietary iPSC product platform is reported to enable mass production of off-the-shelf, engineered, homogeneous cell products that can be administered in repeat doses to mediate more effective pharmacologic activity, including in combination with cycles of other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be reproducibly produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf to treat many patients. Fate Therapeutics’ iPSC product platform is supported by an intellectual property portfolio of over 100 issued patents and 100 pending patent applications.

On Monday, September 17th, Fate Therapeutics, Inc. announced that it has entered into a collaboration with Tokyo-based ONO Pharmaceutical Co., Ltd. (approximately 300-year-old organization) for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics will receive an upfront payment and committed research funding during the preclinical option period, and is eligible to receive a preclinical option exercise fee, clinical, regulatory and commercialization milestone payments and tiered royalties on net sales by ONO in connection with the development and commercialization of each collaboration product by ONO in the ONO territory.

 

 

 

Using Fate Therapeutics’ proprietary induced pluripotent stem cell (iPSC) product platform, the two CAR T-cell collaboration candidates will each be derived from a clonal master iPSC line engineered to completely eliminate endogenous TCR expression, insert a chimeric antigen receptor (CAR) into the TRAC locus and incorporate other anti-tumor functionality. This transformative approach enables the cost-effective production of cell-based cancer immunotherapies that are uniformly engineered, extensively characterized and homogeneous in composition, and can be consistently and repeatedly mass produced and delivered to patients in an off-the-shelf manner.

Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are delighted to collaborate with ONO, a global leader in oncology with a long history of developing innovative breakthrough cancer drugs. This partnership with ONO enables Fate to further enhance its expertise in targeting solid tumors and to accelerate the global development of our pipeline of off-the-shelf, iPSC-derived CAR-T cell product candidates.”

Under the terms of the strategic option agreement, Fate Therapeutics and ONO will jointly advance each iPSC-derived CAR-T cell collaboration candidate to a pre-defined preclinical milestone.

  • The first iPSC-derived CAR T-cell candidate targets an antigen expressed on certain lymphoblastic leukemias, and Fate Therapeutics retains global responsibility for development and commercialization with ONO having an option to assume responsibilities in Asia.
  • The second candidate targets a novel antigen identified by ONO expressed on certain solid tumors, with ONO having an option to assume global responsibility for further development and commercialization and Fate Therapeutics retaining the right to co-develop and co-commercialize the candidate in the United States and Europe. For both collaboration candidates, Fate Therapeutics retains manufacturing responsibilities on a global basis.

Hiromu Habashita, Corporate Officer, and Executive Director of Discovery & Research of ONO stated, “ONO identified Fate Therapeutics as the partner of choice for the generation of off-the-shelf CAR T-cell cancer immunotherapies in our portfolio. We are excited to work with Fate Therapeutics and apply its industry-leading iPSC product platform to develop and deliver the next-generation of CAR T-cell therapies for cancer patients.”

 

 

If you found this story interesting you should consider reading about Seattle-based Atossa Genetics (Nasdaq: ATOS) which is is a clinical-stage drug company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. To learn more please see the dedicated coverage page at Vista Partners.

Fate Therapeutics Announces Strategic Collaboration with ONO Pharmaceutical to Develop Off-the-Shelf, iPSC-derived CAR-T Cell Cancer Immunotherapies

Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that it has entered into a collaboration with ONO Pharmaceutical Co., Ltd. for the joint development and commercialization..

finance.yahoo.com

Read Full Article



Have You Read “Vista Partners Weekly Market Update 9-15-18?”

Vista Partners published “Vista Partners Weekly Market Update 9-15-18!” 

Each weekly issue is written by Vista Partners’ Managing Director, John Heerdink!

Each weekly issue includes updates on the stock market, a “Stocks To Watch” section, & featured daily stories & videos from Vista’s Coverage Universe of Dow 30 components, International and Select Emerging Growth Companies & more.

 Download the latest Exclusive FREE Newsletter at the Vista Partners’ Newsletters Page now.

Stay Informed! Stay Competitive!  Receive our FREE updates by signing up today!

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.




Atossa Advancing Into Phase 2 Study to Reduce Gynecomastia In Men Starting Prostate Cancer Therapy

Gynecomastia is male breast enlargement and accompanying pain, which according to the Mayo Clinic, affects 25% of men in the U.S. between the ages of 50-69, or approximately 10 million men. It is the most common male breast disorder and is caused by a hormone imbalance where testosterone levels are lower than estrogen. Gynecomastia is caused by, among other things, any number of commonly prescribed medications, such as androgen deprivation therapy to treat prostate enlargement and prostate cancer, anti-anxiety medications, cancer treatments (chemotherapy), and some heart medications.

Gynecomastia is not only painful and embarrassing, it can also cause men to stop taking their prescribed medication. In prostate cancer treatment, testosterone is suppressed resulting in higher estrogen levels that often triggers gynecomastia. One recent study indicates that up to 90% of men taking androgen deprivation therapy suffer from gynecomastia and breast pain (Handoo Rhee, et al., October 18, 2014, BJU International).

There is no FDA-approved pharmaceutical to treat gynecomastia. Current therapeutic approaches in these patients include the use of daily oral estrogen-suppressing medications and prophylactic breast bud irradiation which is often repeated. Gynecomastia can create quality of life issues, with some patients attempting to hide the condition with compression garments and, in some cases, undergoing plastic surgery.

Seattle-based Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported earlier today their preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects. All objectives were announced to have been successfully met as follows:

  • Safety: There were no clinically significant safety signals and no clinically significant adverse events in participants receiving topical Endoxifen.
  • Tolerability: Topical Endoxifen was well tolerated at each dose level and for the dosing duration utilized in the study.
  • Pharmacokinetics: Blood samples showed no measurable topical Endoxifen.

 

 

 

 

 

Dr. Steven C. Quay, CEO, and President of Atossa stated, “Based on these positive preliminary results, we are advancing our topical Endoxifen into a Phase 2 study to reduce gynecomastia in men starting prostate cancer therapy. We anticipate retaining a clinical research organization to manage that study in the fourth quarter of 2018. In addition to advancing our mens’ program into a Phase 2 study, we also have multiple Phase 2 studies in women addressing large markets with significant unmet needs: breast cancer and a condition called mammographic breast density. We look forward to reporting progress on these programs in the fourth quarter of 2018 and into 2019.”

 

 

 

 

 

Conference Call

Atossa Genetics hosted a conference call to discuss preliminary results today at 10 am Eastern time. A replay of the call will be available approximately one hour after the end of the call through October 13, 2018. The replay can be accessed via Atossa’s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll-Free at 855-669-9658. The replay access code is 10124008.

 

 

 

 

 

Learn More

To learn more about Atossa Genetics (ATOS) and to track its ongoing progress, please visit the Vista Partners Atossa Genetics Coverage Page.

Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported preliminary results from its Phase 1 dose- escalation study of its proprietary topical Endoxifen in male subjects…

finance.yahoo.com

Read Full Article



MARKET ALERT: Atossa To Discuss Preliminary Results of Phase 1 Study Of Proprietary Topical Endoxifen In Men On September 13th

Seattle -based Atossa Genetics Inc. (NASDAQ: ATOS) is a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions.

Atossa announced today prior to the markets open that it will host a conference call on September 13, 2018, at 10 am EDT to discuss preliminary results from its Phase 1 dose-escalation study of its proprietary topical Endoxifen in male subjects. The Phase 1 study was a double-blind, placebo-controlled, repeat dose study of 24 healthy male subjects. Atossa assessed safety, tolerability and the pharmacokinetics of proprietary formulations of topical Endoxifen at varying dose levels over 28 days. The study was conducted on behalf of Atossa by CPR Pharma Services Pty Ltd., Thebarton, SA, Australia.

To participate, investors may dial 1-844-824-3830 (domestic), 1-412-317-5140 (international) and Canada Toll Free: 1-855-669-9657. Callers should ask to be joined into the Atossa Genetics call. The conference call will also be available through a live webcast at https://services.choruscall.com/links/atos180913.html which is also available at www.atossagenetics.com on the Company’s IR events page at http://ir.atossagenetics.com/ir-calendar. A replay of the call will be available approximately one hour after the end of the call through October 13, 2018. The replay can be accessed via Atossa’s website or by dialing 877-344-7529 (domestic) or 412-317-0088 (international) or Canada Toll-Free at 855-669-9658. The replay access code is 10124008.

Atossa shares have spiked in early trading to a high of $2.30/share on ~1.33 million shares of trading. The day low is $1.81/share.

Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call on September 13, 2018 at 10 am EDT to discuss preliminary results from its Phase 1 dose-escalation..

finance.yahoo.com

Read Full Article



Listen to The Groundwork Forum Podcast Interview of Steven Quay CEO of Atossa Titled “What Is Gynecomastia?”

The Groundwork Forum Podcast aims to bring together leaders from all disciplines all over the world to join its Global Community to consider new perspectives on key issues; to create a powerful, global network in order to strengthen the influence throughout the world; to draw up innovative and concrete action plans to encourage contribution to society; and to promote diversity in the business world.

The most recent Groundwork Forum Podcast Episode features an interview with Atossa Genetics (ATOS) CEO Steven Quay MD, Ph.D. and is titled “What Is Gynecomastia?”  Up to 70 percent of boys in early to mid-puberty experience gynecomastia because of the normal hormonal changes that occur during puberty. Gynecomastia is also common among middle-aged and older men. In this population, up to 65 percent of men are affected.

Dr. Quay is the  Chief Executive Officer, President, and Chairman of the Board of Directors of Atossa Genetics (NasdaqCM: ATOS), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions.  Dr. Quay is certified in Anatomic Pathology with the American Board of Pathology, completed both an internship and residency in anatomic pathology at Massachusetts General Hospital, a Harvard Medical School teaching hospital, and is a former faculty member of the Department of Pathology, Stanford University School of Medicine.  Dr. Quay is a named inventor on 87 U.S. patents, 130 pending U.S. patent applications, and is named inventor on patents covering five pharmaceutical products that have been approved by the U.S. Food and Drug Administration.  

To listen to the podcast, visit https://www.vistapglobal.com/groundwork-forum/.

Fans of the podcast can contact inquiries@vistapglobal.com via email or provide feedback and ideas for the podcast.

Based in San Francisco the Groundwork Forum is hosted by John Heerdink, Managing Director of Vista Partners LLC. The Groundwork Forum is released periodically and is available for free at https://www.vistapglobal.com/groundwork-forum/.

Founded in 2005, Vista Partners LLC (“Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, The Groundwork Forum Podcast and Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

We encourage readers to view a complete list of disclaimers and disclosures on the Vista Partners website at VistaPGlobal.com/disclaimer.

Please follow Vista Partners on Twitter @VistaPResearch to receive updates, thoughts, and ideas on Dow 30 Components, Select Emerging Growth Companies, Vista’s Featured Companies, International Companies, Pre-IPO Companies & Strategic Companies.

Contact:

inquiries@VistaPGlobal.com

 

 




“Predictably South” Vista Partners Weekly Market Update 9-8-18

Vista Partners has published “Predictably South” Vista Partners Weekly Market Update 9-8-18and is accessible on our Newsletters Page. Each issue is written by the Managing Director, John Heerdink and speaks to the activities of the market, influencers and specific featured stories from Vista’s Coverage Universe that spans the Dow 30, International and Select Emerging Growth Companies & “Investor Picks”, where we have begun to selectively add those companies/ideas that we are receiving from investors around the world.

Newsletter topics include but are not limited to the following: investing, banks, world news, entertainment & movie industry, cryptocurrencies, healthcare, biotech, mining, technology, cybersecurity, & consumer trends.

Each weekly update issue is sent out via email directly to the thousands of investors around the world that have elected to be updated each week. Please “Join us” Today!

 

 

 

 

 

 

Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.

Stay Informed! Stay Competitive!

Join us at Vista Partners! It’s FREE to receive email updates.